Full-Time

Clinical Safety Coordinator

Pharmacovigilance / Drug Safety

Confirmed live in the last 24 hours

Medpace, Inc.

Medpace, Inc.

1,001-5,000 employees

No salary listed

Junior, Mid

London, UK

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Minimum Bachelor’s life science degree
  • 2+ years of Clinical Trial Pharmacovigilance experience
  • Working knowledge of Safety Databases (Argus is desirable)
  • Demonstrate advanced knowledge of medical terminology, global safety reporting requirements and Good Clinical Practice (GCP) Guidelines
  • Exposure to working on global trials as part of a multidisciplinary team
Responsibilities
  • Collect, process, and track serious adverse event (SAE) reports
  • Generate safety narratives and queries
  • Safety Database data entry
  • Perform quality control of safety cases
  • Generate Investigator Safety Letters
  • SAE reconciliation between safety database and clinical database
  • TMF uploads and quality control review
  • Preparation of clinical safety documents as required (i.e., safety management plan, periodic safety reports and presentations)
  • Attending internal and external meetings, as required (including sponsor TCs and audits/inspections)
  • Leading clinical trial projects (ensure client deliverables are met, provide oversight and compliance reports)
  • Develop presentation material and present during face-to-face Sponsor meetings (i.e., Kick-off Meetings, Investigator Meetings)
  • Coordinate final medical review of study report narratives and submission to Medical Writers
  • Develop drafts of adjudication material (i.e., charter, reporting materials)
  • Provide periodic safety summaries to project Data Manager, Clinical Trial Manager, and Medical Monitor
  • Train new Clinical Safety Coordinators on safety reporting responsibilities
  • Coordinate safety responsibilities for aggregate reporting purposes (e.g., ensure timely data entry, tracking of pending cases, collaborate with Medical Monitor and Regulatory Affairs)
Desired Qualifications
  • Argus is desirable

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Irving, Texas

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • Significant revenue growth in Q4 2023 indicates strong market demand and effective strategies.
  • Recent investments by financial institutions reflect confidence in Medpace's growth potential.
  • Expansion of medical leadership team suggests increased focus on clinical research and development.

What critics are saying

  • Increased competition from Lantheus and others may pressure Medpace's market share.
  • New Cincinnati office construction could lead to higher operational costs and project delays.
  • Decreased net income margin in 2023 indicates challenges in maintaining profitability.

What makes Medpace, Inc. unique

  • Medpace's expansion in infectious diseases and vaccines shows strategic focus on high-demand sectors.
  • New leadership in respiratory and women's health enhances Medpace's expertise and service offerings.
  • Commitment to infrastructure growth with new Cincinnati office supports future operational efficiency.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Unlimited Paid Time Off

Competitive Compensation and Benefits Package

Employee Health and Wellness Initiatives

Hybrid Work Options

Structured Career Paths with Opportunities for Professional Growth

Company News

Financial Modeling Prep
Feb 28th, 2025
Lantheus Holdings, Inc. (NASDAQ:LNTH) Demonstrates Strong Capital Efficiency

Lantheus competes with other companies in the medical and pharmaceutical industries, such as ShockWave Medical, Medpace Holdings, LivaNova, Apellis Pharmaceuticals, and Natera.

Stock Titan
Aug 15th, 2024
Skanska builds new office building in Cincinnati, Ohio, USA, for USD 164M, about SEK 1.7 billion

STOCKHOLM, Aug. 15, 2024 /PRNewswire/ - Skanska has signed a contract with Medpace, a clinical research company, for the construction of a new office building in Cincinnati, Ohio, USA.

MarketBeat
Apr 8th, 2024
First National Bank of Hutchinson Invests $786,000 in Medpace Holdings, Inc. (NASDAQ:MEDP)

First National Bank of Hutchinson invests $786,000 in Medpace Holdings, Inc. (NASDAQ:MEDP).

PharmiWeb
Feb 13th, 2024
Medpace Holdings, Inc. Reports Fourth Quarter And Full Year 2023 Results

Revenue of $498.4 million in the fourth quarter of 2023 increased 26.5% from revenue of $394.1 million for the comparable prior-year period, representing a backlog conversion rate of 18.5%.Net new business awards were $614.7 million in the fourth quarter of 2023, representing an increase of 26.7% from net new business awards of $485.1 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.23x.Fourth quarter of 2023 GAAP net income was $78.3 million, or $2.46 per diluted share, versus GAAP net income of $68.7 million, or $2.12 per diluted share, for the comparable prior-year period. Net income margin was 15.7% and 17.4% for the fourth quarter of 2023 and 2022, respectively.EBITDA was $95.8 million for the fourth quarter of 2023, an increase of 19.2% from EBITDA of $80.4 million for the comparable prior-year period, resulting in an EBITDA margin of 19.2%. CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Results

MarketBeat
Feb 2nd, 2024
Hussman Strategic Advisors Inc. Invests $1.02 Million in Medpace Holdings, Inc. (NASDAQ:MEDP)

Hussman Strategic Advisors Inc. invests $1.02 million in Medpace Holdings, Inc. (NASDAQ:MEDP).